Sentences with phrase «median overall survival for»

The median overall survival for napabucasin was 4.4 months compared with 4.8 months for placebo.

The median overall survival for previously untreated patients was 18.6 months.

Median overall survival for woman in the chemotherapy plus bevacizumab treatment was 42.2 months, compared with 37.3 for those receiving chemotherapy alone.

Median overall survival for patients on selumetinib was 11.8 months, compared with 9.1 months for those on chemotherapy, but the difference was not statistically significant.

Not exact matches

«Patients who respond to immunotherapy tend to continue their responses for long durations, and these lengthier responses are cut off in calculations of median overall survival,» she says.

Median overall survival of patients receiving nivolumab was 9.2 months, compared with six months for patients who received docetaxel.

«Similarly 71 drugs approved by the FDA from 2002 to 2014 for solid tumours have resulted in median gains in progression - free and overall survival of only 2.5 and 2.1 months, respectively,» he says adding, «Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee's criteria for meaningful results for patients.»

In a study presented today at a meeting of women's cancer specialists, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.

Median overall survival was 10.4 months for SRS alone and 7.4 months for SRS plus WBRT.

Mean progression - free survival was 3.1 months with regorafenib and 1.5 months with placebo, while median overall survival was 10.6 months for regorafenib and 7.8 months with placebo.

At five years, 34 of the 102 patients had achieved a complete response (disappearance of their cancer for a period of time), with an estimated 64 percent of patients surviving with or without disease (median five - year overall survival was 40.5 months) and an estimated 52 percent surviving without disease progression.

At five years, the rates for disease - free and overall survival were 26 percent and 40 percent, respectively, with a median overall survival of four years.

This translated into a median overall survival of 57.6 months for men who received early chemotherapy compared with 44 months in the group given ADT as the only initial treatment — more than a year of additional life.

The median overall survival was 9 months in the entire chemotherapy group and 7.7 months in the erlotinib group, for a hazard ratio of 1.14 (95 % CI, 0.88 — 1.49; P = 0.313).

In RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old, NCT00651261), for which Stone was first author, median overall survival was 74.7 months with chemotherapy plus midostaurin and 25.6 months with chemotherapy plus placebo (P = 0.009).

The treatment resulted in a median overall survival (OS) of longer than 3 years in both arms of the trial (median OS, 38.2 months for irradiation vs 36.6 months for nonmyeloablating chemotherapy alone; hazard ratio, 1.11 [95 % CI, 0.65 — 1.91]-RRB-.

For newly diagnosed GBM patients treated with current standard of care, median progression free survival is just 6.9 months, and median overall survival is 14.6 months.